SBIR and STTR Success Story for
VisualShare, Inc.

(Information Posted/Updated on 02/28/2009)

VisualShare, Inc.
350 E. 500 S. #101
Salt Lake City, UT  84111

Contact:    Patricia Goede
Phone:      801-931-6052
Fax:          801-931-6051
E-mail:      pgoede@visualshare.com
Web Site:  http://www.visualshare.com

Project Title:  Teleconsultation and Quality Review in Child Maltreatment
Related Award(s):  R44 HD052329
Technology Developed:
Image-based telehealth technology solutions that connect providers and victims of child abuse in rural and underserved community clinics with experts in tertiary care centers across the United States. The technology (TeleCAM™) supported by SBIR funding, has improved efficiencies in diagnostic evaluation and treatment of victims of child abuse by 32% and is currently in the market place as a commercial product.

Key Words:  child abuse, child maltreatment, Image collaboration, quality review, peer review, telehealth, diagnosis, TeleCAM™.
Uses of Technology/Products/Service:
TeleCAM™ is a web-based telehealth technology for physicians and providers associated with child abuse medical evaluation that require a solution for diagnostic services to providers in rural and underserved communities. TeleCAM™ provides access to medical providers located in rural communities that typically do not have the means to link up to a traditional or dedicated telemedicine infrastructure that could be used for clinical peer review and diagnosis. TeleCAM™ tracks the incremental accumulation of case material—images (photo-documentation) and text—from initial creation at a remote clinic through to the final evaluation by a consulting physician, typically located at a hospital or tertiary care center. Accurate and timely diagnosis is supported between two or more providers that share information or evidence consisting of case images (photo-documentation) while maintaining a consultation record for reimbursement and reporting.

The innovative core technology that provides and supports text image-based communication for TeleCAM™ has been used in other areas of clinical telehealth. For example, the core technology for child abuse is now used to provide routine screenings for adults with diabetic retinopathy and premature newborn infants with retinopathy of prematurity (ROP). Diabetes is increasing and the use of retinal imaging is the first non-invasive step in diagnosing diabetes in adults. ROP in infants is a condition that if not caught early, can lead to blindness. VisualShare’s telehealth technology is critical and cost effective and allows for early detection by reducing the time to diagnosis and treatment.

Additional applications: -teledermatology -telepathology -mobile cardiology -preclinical imaging -late phase clinical trial adjudication

Benefit to Company:
VisualShare has been very fortunate to receive SBIR funding and was able to accomplish the goal of developing core technology to increase efficiencies in diagnosis and treatment in child abuse and other clinical specialties that involve images and providers that are geographically distant from one another. SBIR funded research and development created interest from child abuse early adopters and generated program income from other clinical imaging specialties including pathology, cardiology and ophthalmology. In addition, in late 2008, VisualShare was able to attract investment capital to support additional research and development, support and sales and marketing into pathology, ophthalmology and preclinical imaging in clinical trials.

How Product Was Commercialized:
Commercialization efforts are focused around presentations and displays at professional conferences (e.g., Child Maltreatment, American Telemedicine Association, BioIT Life Sciences), developing partnerships with tertiary care centers that provide services to in/out network providers and word of mouth from early adopters. Future commercialization endeavors will involve hiring sales and marketing to penetrate clinical imaging markets outside of child abuse.

Past R&D and/or Sales from this Project:   $110,000
Estimated Future Annual R&D and/or Sales from this Project:   $2.7M